TML-ML18147

NCT00700102 📎

Regimen

Experimental
Bevacizumab (continued, same dose) + chemotherapy switch (oxaliplatin→irinotecan or vice versa)
Control
Chemotherapy switch alone (no bevacizumab continuation)

Population

Metastatic CRC, 2L, after progression on first-line bevacizumab-containing chemotherapy.

Key finding

2L mCRC (post-1L bev+chemo): mOS 11.2 vs 9.8 mo (HR 0.81, 95% CI 0.69-0.94, p=0.0062); mPFS 5.7 vs 4.1 mo (HR 0.68, 95% CI 0.59-0.78, p<0.0001); chemotherapy switch (oxaliplatin↔irinotecan) plus continued bevacizumab at progression

Source: PMID 23168366

Timeline

    Guideline citations

    • NCCN Colon (p.59)
    • NCCN Rectal (p.57)